Today's slide is the latest in a sustained pullback for Clarity, which has now been down approximately 26 per cent over the past one month. The broader sell-off in Australian clinical-stage biotech – Neuren Pharmaceuticals (ASX:NEU) fell 1.24 per cent today – is consistent …
CSL Limited (ASX:CSL) remains one of Australia's most closely followed healthcare companies, but recent developments have shifted the conversation from growth expectations to execution and recovery. The biotechnology giant, known globally for its plasma therapies, influenza vaccines and specialty medicines, has entered a period …
Opthea Limited (ASX:OPT) fell sharply on its return to ASX trading on June 3, 2026, declining 97.17% to A$0.017. The extent of the fall reflects the accumulated uncertainty that built during theTrading haltperiod following the company's failed Phase 3Clinical Trialsfor wet age-related macular degeneration …
Micro-X (ASX:MX1) shares edged higher on June 3, rising 2.56% to A$0.040 after the medical imaging technology company announced a significant milestone in the development of its Head CT scanner. The company revealed that the first human patient images had been acquired using its …
Cynata Therapeutics Ltd (ASX:CYP) shares advanced 7.27% to AUD 0.30 during the afternoon session on 3 June 2026 after the clinical-stage biotechnology company announced a favourable regulatory development for its lead cell therapy candidate, CYP-001. The gain adds to an already notable longer-term performance, …
Pacific Edge Limited (ASX:PEB), a New Zealand-headquartered cancer diagnostics company, completed its NZ$36.1M capital raising on 3 June 2026 with the allotment of shares under its retail offer. The company develops and commercialises the Cxbladder suite of non-invasive genomic urine tests, which are used …
Biome Australia Limited (ASX:BIO) surged 20.00% on 3 June 2026 to trade at A$0.27, as the company announced it had signed a commercial manufacturing agreement with Specialty Probiotics Australia (SPA) — a domestic GMP-licensed probiotic manufacturer. The announcement marks the execution of Phase One …
The downward movement in Artrya Limited (ASX:AYA) on 2 June 2026 highlights the volatile trading patterns frequently observed among emerging healthcare equipment and services listings on the Australian Securities Exchange. Closing the session at A$4.680, the share price fluctuated visibly throughout the day. Despite …
Austco Healthcare Ltd (ASX:AHC) was among the weaker performers on the Australian market on 2 June 2026, with shares falling 9.62% to A$0.235. The decline drew attention from investors as the healthcare technology company experienced substantially higher trading activity than usual.
Shares in PolyNovo Ltd (ASX:PNV) were among the biggest losers on the Australian share market on 2 June 2026, with the stock falling 5.15% to AUD 1.10 based on available market data. The move placed PolyNovo on the list of the day's worst-performing ASX …